Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Emma A. Harden"'
Autor:
Vasyl Kovalishyn, Oleksandr Severin, Maryna Kachaeva, Oleksandr Kobzar, Kathy A. Keith, Emma A. Harden, Caroll B. Hartline, Scott H. James, Andriy Vovk, Volodymyr Brovarets
Publikováno v:
Molecular Biotechnology.
Autor:
Vasyl Kovalishyn, Kathy A. Keith, Emma A. Harden, Maryna V. Kachaeva, Kostiantyn Ziabrev, Volodymyr Zyabrev, Volodymyr Brovarets, Caroll B. Hartline, Scott H. James
Publikováno v:
Journal of Computer-Aided Molecular Design. 35:1177-1187
The problem of designing new antiviral drugs against Human Cytomegalovirus (HCMV) was addressed using the Online Chemical Modeling Environment (OCHEM). Data on compound antiviral activity to human organisms were collected from the literature and uplo
Autor:
Elke Lipka, Aaron M. Chadderdon, Cheryl C. Harteg, Matthew K. Doherty, Eric S. Simon, John M. Domagala, Dawn M. Reyna, Kim M. Hutchings, Xinmin Gan, Andrew D. White, Caroll B. Hartline, Emma A. Harden, Kathy A. Keith, Mark N. Prichard, Scott H. James, Rhonda D. Cardin, David I. Bernstein, Jacqueline F. Spencer, Ann E. Tollefson, William S. M. Wold, Karoly Toth
Publikováno v:
Molecular pharmaceutics. 20(1)
DNA viruses are responsible for many diseases in humans. Current treatments are often limited by toxicity, as in the case of cidofovir (CDV, Vistide), a compound used against cytomegalovirus (CMV) and adenovirus (AdV) infections. CDV is a polar molec
Autor:
Stepan G. Pilyo, Victor V. Zhirnov, V. S. Brovarets, Emma A. Harden, Mark N. Prichard, Nataliya V. Velychko, Mykhailo Y. Brusnakov, Scott H. James, Oleksandr V. Golovchenko, E. R. Abdurakhmanova
Publikováno v:
Medicinal Chemistry Research. 29:1669-1675
A series of derivatives of 5-hydroxyalkylamino-1,3-oxazoles were synthesized. Among these derivatives, 5 compounds have been evaluated for their activities against a normal laboratory human cytomegalovirus (HCMV) strain, AD169, in human foreskin fibr
Autor:
Emma A. Harden, Volodymyr Brovarets, Caroll B. Hartline, Victor V. Zhirnov, Maryna V. Kachaeva, Stepan G. Pilyo, Mark N. Prichard
Publikováno v:
Medicinal Chemistry Research. 28:1205-1211
Ten 5-functionalized derivatives of 1,3-oxazole-4-carboxylate and 1,3-oxazole-4-carbonitrile were synthesized and their antiviral activities against the human cytomegalovirus (HCMV) were evaluated in vitro. Bioassays showed that seven compounds exhib
Autor:
Tracy L. Hartman, Robert W. Buckheit, Kathy A. Keith, Jei-Hwa Yu, Louise T. Chow, Nadejda Valiaeva, James R. Beadle, Emma A. Harden, Thomas R. Broker, Mark N. Prichard, Karl Y. Hostetler, Guang Yang, Kathy A. Aldern
Publikováno v:
Journal of Medicinal Chemistry. 59:10470-10478
Human papillomavirus (HPV) high-risk genotypes such as HPV-16 and HPV-18 cause the majority of anogenital tract carcinomas, including cervical cancer, the second most common malignancy in women worldwide. Currently there are no approved antiviral age
Autor:
Jessica Eagar, Emma A. Harden, Caroll B. Hartline, Terry L. Bowlin, Kathy A. Keith, Mark N. Prichard
Publikováno v:
Antiviral research. 159
The search for new compounds with a broad spectrum of antiviral activity is important and requires the evaluation of many compounds against several distinct viruses. Researchers attempting to develop new antiviral therapies for DNA virus infections c
Publikováno v:
Antiviral Research. 83:282-289
Herpes simplex virus types 1 and 2 (HSV-1, HSV-2) infections are common, but can cause serious infections in neonates and the immunocompromised. Drugs currently used to treat cutaneous or genital HSV infections are effective in limiting disease, but
Autor:
W. Brad Wan, Mark N. Prichard, Shannon Daily, Caroll B. Hartline, Karl Y. Hostetler, James R. Beadle, Nicole L. Kushner, Earl R. Kern, Emma A. Harden, Stephanie L. Williams-Aziz
Publikováno v:
Antimicrobial Agents and Chemotherapy. 49:3724-3733
Cidofovir (CDV) is an effective therapy for certain human cytomegalovirus (HCMV) infections in immunocompromised patients that are resistant to other antiviral drugs, but the compound is not active orally. To improve oral bioavailability, a series of
Autor:
Earl R. Kern, Karen K. Biron, Stephanie L. Williams, Emma A. Harden, Leroy B. Townsend, Deborah J. Bidanset, Mark R. Underwood, John C. Drach, Nicole L. Kushner, Caroll B. Hartline
Publikováno v:
Antimicrobial Agents and Chemotherapy. 47:2186-2192
Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and human herpesvirus 8 (HHV-8) are responsible for a number of clinical manifestations